Nabriva Therapeutics AG (NASDAQ:NBRV) had its target price increased by SunTrust Banks, Inc. from $20.00 to $24.00 in a research report report published on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other research analysts also recently issued reports on the stock. Cantor Fitzgerald reaffirmed a buy rating and issued a $16.00 price objective on shares of Nabriva Therapeutics AG in a research report on Monday. HC Wainwright reissued a buy rating and set a $18.00 target price (up previously from $16.00) on shares of Nabriva Therapeutics AG in a research report on Monday, August 28th. Zacks Investment Research downgraded shares of Nabriva Therapeutics AG from a buy rating to a hold rating in a research report on Tuesday, August 15th. Finally, ValuEngine downgraded shares of Nabriva Therapeutics AG from a hold rating to a sell rating in a research report on Tuesday, August 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Nabriva Therapeutics AG currently has an average rating of Buy and a consensus price target of $19.13.
Nabriva Therapeutics AG (NASDAQ NBRV) opened at 8.26 on Monday. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $14.10. The company’s market cap is $221.68 million. The company’s 50-day moving average is $9.01 and its 200-day moving average is $10.19.
Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.83) by $5.29. The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.34 million. On average, equities research analysts expect that Nabriva Therapeutics AG will post ($2.29) EPS for the current fiscal year.
WARNING: This article was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://sportsperspectives.com/2017/09/21/suntrust-banks-inc-boosts-nabriva-therapeutics-ag-nbrv-price-target-to-24-00.html.
In other Nabriva Therapeutics AG news, major shareholder Hbm Healthcare Investments (Ca sold 13,127 shares of Nabriva Therapeutics AG stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $10.94, for a total transaction of $143,609.38. Following the completion of the sale, the insider now directly owns 2,583,229 shares in the company, valued at approximately $28,260,525.26. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of the firm’s stock in a transaction on Monday, September 18th. The shares were acquired at an average price of $9.46 per share, with a total value of $497,889.26. The disclosure for this purchase can be found here. In the last three months, insiders have sold 279,000 shares of company stock worth $2,870,869. 2.75% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Royal Bank of Canada lifted its stake in Nabriva Therapeutics AG by 19.6% during the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after acquiring an additional 8,650 shares during the period. Almanack Investment Partners LLC. acquired a new stake in Nabriva Therapeutics AG during the 1st quarter valued at approximately $1,870,000. Nationwide Fund Advisors acquired a new stake in Nabriva Therapeutics AG during the 1st quarter valued at approximately $2,074,000. Finally, Wellington Management Group LLP lifted its stake in Nabriva Therapeutics AG by 9.9% during the 1st quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after acquiring an additional 193,951 shares during the period. Institutional investors and hedge funds own 68.56% of the company’s stock.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.